When novel drugs and biologics hit the market, the treatment horizon for many patients is suddenly broadened. US Food and Drug Administration (FDA) ‘firsts’ can …
The current COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, is the current focus of numerous drug therapies and vaccine candidates. We have seen swift …
At the peak of the COVID-19 pandemic, clinical study monitors and patients were restricted from sites. Sponsors and CROs had to reassesshow to keep trials …
Within this evolving world of biopharma, it is estimated that two-thirds of biopharmaceutical manufacturing is outsourced. Therefore, the supplychain is not only complex, but also …
The pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are immense – and soaring. So why are Safety & Pharmacovigilance …
Contact-tracing apps and technologies are a hotly debated issue with legal, medical and technological implications. The most common mistake in the public debate is to …
The outbreak of COVID-19 created unprecedented circumstances for the conduct of clinical trials across the world. While the industry has experienced challenging conditions in managing …
Clinical research is a complex, expensive, and time- and resourceintensive process. Feasibility assessments play a crucial part in this clinical research planning process as it …
The medical device industry makes a colossal number of items ranging from invasive gloves to non-natural joints to imaging gear andassumes a pivotal job in …
The low representation of African countries in clinical trials is not unusual. Poor visibility of existing sites, limited infrastructure, cultural barriers, misunderstandings of requirements to …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.